Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86


Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095.


Reply to H.J.A. Adams et al.

Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA.

J Clin Oncol. 2019 Feb 11:JCO1802297. doi: 10.1200/JCO.18.02297. [Epub ahead of print] No abstract available.


Medical financial hardship among cancer survivors in the United States.

Zheng Z, Jemal A, Han X, Guy GP Jr, Li C, Davidoff AJ, Banegas MP, Ekwueme DU, Yabroff KR.

Cancer. 2019 Jan 21. doi: 10.1002/cncr.31913. [Epub ahead of print]


Trends in Antineoplastic Receipt after Medicare Payment Reform: Implications for Future Oncology Payment Design.

Parsons HM, Schmidt S, Tenner LL, Davidoff AJ.

J Cancer Policy. 2018 Sep;17:51-58. doi: 10.1016/j.jcpo.2016.09.008. Epub 2016 Sep 28.


The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

Blood Adv. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436.


Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA.

J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122. [Epub ahead of print]


Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ.

Cancer. 2018 Nov 1;124(21):4211-4220. doi: 10.1002/cncr.31688. Epub 2018 Sep 14.


Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.

Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ.

J Clin Oncol. 2018 Oct 1;36(28):2879-2886. doi: 10.1200/JCO.2018.77.8894. Epub 2018 Aug 16.


Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber AL, Davidoff AJ, Sedghi T, Gross CP.

Breast Cancer Res Treat. 2018 Nov;172(2):453-461. doi: 10.1007/s10549-018-4919-3. Epub 2018 Aug 11.


Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults.

Presley CJ, Han L, Leo-Summers L, Hurria A, Gross CP, Davidoff AJ, Allore HG, Gill TM.

J Geriatr Oncol. 2019 Jan;10(1):60-67. doi: 10.1016/j.jgo.2018.05.017. Epub 2018 Jun 22.


Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD.

Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8. No abstract available.


Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups.

Sheffield KM, Bowman L, Smith DM, Li L, Hess LM, Montejano LB, Willson TM, Davidoff AJ.

J Comp Eff Res. 2018 Mar;7(3):193-208. doi: 10.2217/cer-2017-0040. Epub 2018 Mar 13.


Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History: Population-based National Estimates.

Davidoff AJ, Guy GP Jr, Hu X, Gonzales F, Han X, Zheng Z, Parsons H, Ekwueme DU, Jemal A.

Med Care. 2018 Mar;56(3):220-227. doi: 10.1097/MLR.0000000000000876.


Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ.

Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19. No abstract available.


Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ.

PLoS One. 2017 Sep 13;12(9):e0184747. doi: 10.1371/journal.pone.0184747. eCollection 2017.


Changes in Insurance Coverage and Stage at Diagnosis Among Nonelderly Patients With Cancer After the Affordable Care Act.

Jemal A, Lin CC, Davidoff AJ, Han X.

J Clin Oncol. 2017 Dec 10;35(35):3906-3915. doi: 10.1200/JCO.2017.73.7817. Epub 2017 Sep 8.


US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box.

Zeidan AM, Gore SD, Davidoff AJ.

J Clin Oncol. 2017 Oct 1;35(28):3264. doi: 10.1200/JCO.2017.74.3104. Epub 2017 Aug 8. No abstract available.


Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X.

J Clin Oncol. 2017 Oct 20;35(30):3417-3424. doi: 10.1200/JCO.2017.72.7149. Epub 2017 Aug 7.


Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF.

Cancer. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22.


Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ.

Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.


Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN.

J Clin Oncol. 2017 Oct 10;35(29):3306-3314. doi: 10.1200/JCO.2017.72.2447. Epub 2017 May 25.


Low-Income Children With Chronic Conditions Face Increased Costs If Shifted From CHIP To Marketplace Plans.

Peltz A, Davidoff AJ, Gross CP, Rosenthal MS.

Health Aff (Millwood). 2017 Apr 1;36(4):616-625. doi: 10.1377/hlthaff.2016.1280.


Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.

Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS.

J Oncol Pract. 2017 May;13(5):e505-e515. doi: 10.1200/JOP.2016.018341. Epub 2017 Mar 7.


Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States.

Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, Ekwueme DU, Yabroff KR, Jemal A.

Cancer. 2017 Apr 15;123(8):1453-1463. doi: 10.1002/cncr.30560. Epub 2017 Feb 20.


High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D.

Huntington SF, Davidoff AJ.

J Clin Oncol. 2016 Dec 20;34(36):4307-4309. Epub 2016 Nov 14. No abstract available.


Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications.

Qin CX, Sleaby R, Davidoff AJ, Bell JR, De Blasio MJ, Delbridge LM, Chatham JC, Ritchie RH.

Pharmacol Res. 2017 Feb;116:45-56. doi: 10.1016/j.phrs.2016.12.016. Epub 2016 Dec 14. Review.


Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.

Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X.

Prostate. 2017 Apr;77(5):437-445. doi: 10.1002/pros.23281. Epub 2016 Nov 21.


Determinants of Potentially Inappropriate Medication Use among Community-Dwelling Older Adults.

Miller GE, Sarpong EM, Davidoff AJ, Yang EY, Brandt NJ, Fick DM.

Health Serv Res. 2017 Aug;52(4):1534-1549. doi: 10.1111/1475-6773.12562. Epub 2016 Sep 29.


Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD.

Br J Haematol. 2016 Dec;175(5):829-840. doi: 10.1111/bjh.14305. Epub 2016 Sep 21.


Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations.

Encinosa W, Davidoff AJ.

JAMA Oncol. 2017 Mar 1;3(3):320-326. doi: 10.1001/jamaoncol.2016.2530.


Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis.

Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, Yu JB.

Value Health. 2016 Jul-Aug;19(5):631-8. doi: 10.1016/j.jval.2016.02.010. Epub 2016 Apr 7.


Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X.

Leuk Lymphoma. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25. No abstract available.


Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.

Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP.

J Natl Compr Canc Netw. 2016 Aug;14(8):1001-8.


Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial.

Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP.

Ann Surg. 2017 Jan;265(1):39-44. doi: 10.1097/SLA.0000000000001799.


Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.

Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X.

Cancer. 2016 May 15;122(10):1598-607. doi: 10.1002/cncr.29945. Epub 2016 Mar 11.


Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.

Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA.

Cancer. 2016 Apr 15;122(8):1209-15. doi: 10.1002/cncr.29913. Epub 2016 Feb 23.


Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.

Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, Rutter CE, Davidoff AJ, Gross CP.

J Geriatr Oncol. 2016 Jan;7(1):15-23. doi: 10.1016/j.jgo.2015.11.002. Epub 2015 Dec 17.


Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ.

J Comp Eff Res. 2015 Aug;4(4):327-40. doi: 10.2217/cer.15.20.


The Affordable Care Act and Expanded Insurance Eligibility Among Nonelderly Adult Cancer Survivors.

Davidoff AJ, Hill SC, Bernard D, Yabroff KR.

J Natl Cancer Inst. 2015 Jul 1;107(9). pii: djv181. doi: 10.1093/jnci/djv181. Print 2015 Sep.


Changes in Medication Management After a Diagnosis of Cancer Among Medicare Beneficiaries With Diabetes.

Stuart BC, Davidoff AJ, Erten MZ.

J Oncol Pract. 2015 Nov;11(6):429-34. doi: 10.1200/JOP.2014.003046. Epub 2015 Jun 23.


Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ.

Leuk Res. 2015 Jun;39(6):586-91. doi: 10.1016/j.leukres.2015.03.013. Epub 2015 Mar 28.


Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.

Deepak JA, Ng X, Feliciano J, Mao L, Davidoff AJ.

Ann Am Thorac Soc. 2015 May;12(5):742-51. doi: 10.1513/AnnalsATS.201406-230OC.


Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria.

Davidoff AJ, Miller GE, Sarpong EM, Yang E, Brandt N, Fick DM.

J Am Geriatr Soc. 2015 Mar;63(3):486-500. doi: 10.1111/jgs.13320. Epub 2015 Mar 6.


Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.

Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, Gore SD.

J Oncol Pract. 2015 Mar;11(2):e190-8. doi: 10.1200/JOP.2014.001527. Epub 2015 Jan 6.


Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR.

Medicare Medicaid Res Rev. 2014 Nov 26;4(4). pii: mmrr2014-004-04-a02. doi: 10.5600/mmrr.004.04.a02. eCollection 2014. Erratum in: Medicare Medicaid Res Rev. 2014;4(4). pii: mmrr2014-004-04-a02_corrigendum.


Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.

Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA.

Leuk Lymphoma. 2015 Mar;56(3):716-24. doi: 10.3109/10428194.2014.930853. Epub 2014 Aug 6.


Use of and spending on supportive care medications among Medicare beneficiaries with cancer.

Zuckerman IH, Davidoff AJ, Erten MZ, Stuart B, Shaffer T, Dougherty JS, Yong C.

Support Care Cancer. 2014 Aug;22(8):2185-95.


Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.

Davidoff AJ, Gardner LD, Zuckerman IH, Hendrick F, Ke X, Edelman MJ.

Med Care. 2014 Jun;52(6):500-10. doi: 10.1097/MLR.0000000000000122.


The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer.

Erten MZ, Davidoff AJ, Zuckerman IH, Shaffer T, Dougherty JS, Ke X, Stuart B.

Value Health. 2014 Jan-Feb;17(1):15-21. doi: 10.1016/j.jval.2013.11.003.

Supplemental Content

Loading ...
Support Center